Studying Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
Summary
Rationale: Studying samples of blood from HIV-positive patients with cancer in the laboratory may help doctors learn more about changes that occur in the immune system after stem cell transplant.
Purpose: This phase II trial is studying the immune response after stem cell transplant in HIV-positive patients with hematologic cancer.
Description
Primary Objectives:
I. Examine the development of donor-derived HIV-1-specific immune response following HCT for treatment of hematologic malignancy in HIV+ patients.
II. Examine the affect of HCT on the pool of latently infected CD4+ T cells in HIV+ patients given HCT for treatment of hematologic malignancy.
Secondary Objectives:
I. Determine mortality caused by HIV-related events following HCT in HIV+ patients.
II. Determine feasibility of continuous HAART administration after conditioning, defined by number of days off HAART.
III. Examine control of HIV-1 replication after HCT, defined by number of days without evidence of HIV-1 mRNA (viral load).
Outline: Patients undergo leukapheresis for analysis of HIV-1 latent reservoir at baseline and at days +90, +180, and +365. Patients receive conditioning regimen, undergo either allogeneic or autologous marrow or peripheral blood stem cell transplantation, and receive graft-vs-host disease prophylaxis according to standard medical procedures. Patients undergo blood sample collection periodically for biomarker analysis.
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Conditions
Hematopoietic/Lymphoid Cancer
Intervention
leukapheresis, allogeneic hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis, DNA analysis, RNA analysis, flow cytometry, reverse transcrip
Location
Seattle Cancer Care Alliance
Seattle
Washington
United States
98109
Status
Recruiting
Source
Fred Hutchinson Cancer Research Center
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00968630
- Information obtained from ClinicalTrials.gov on July 15, 2010
Published on BioPortfolio: 2014-08-27T03:19:39-0400
Clinical Trials
The objectives of this study are as follows: To demonstrate the safety of escalating doses of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantat...
Mobilization of Stem Cells With AMD3100 in Non-Hodgkin's Lymphoma Patients
The purpose of this study is to determine whether the combination of AMD3100 and G-CSF (filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in n...
Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus
The purpose of this study is to determine if autologous nonmyeloablative hematopoietic stem cell transplantation is able to induce prolonged and significant increases of C-peptide levels a...
The purpose of this study is to develop an alternative treatment for patients with relapsed diffuse large B cell lymphoma who are not likely to be cured by the conventional transplantation...
Humor Therapy and Distress After Allogeneic Stem Cell Transplantation
This research study evaluates the impact of a humor intervention on distress (primary outcome), hope, depressive symptoms, anxiety, and pain (secondary outcomes) in patients undergoing all...
PubMed Articles
For many inborn errors of metabolism (IEM), allogeneic hematopoietic stem cell transplantation (HUSCT) is the only cure.
Relapsed cHL patients after autologous hematopoietic stem cell transplantation (HSCT) with treatment sensitive disease are potential candidates for curative allogeneic HSCT. However, there are some co...
We read with interest the recent paper by Molina and coworkers, who studied the relationship between anti-Pneumocystis prophylaxis and Nocardia infections in allogeneic hematopoietic stem cell transpl...
Pre-transplantation serum ferritin (SF) has been considered to be a potential prognostic biomarker in patients undergoing allogeneic hematopoietic stem cell transplantation (allogeneic HSCT), but this...
Hematopoietic stem-cell transplantation in systemic sclerosis: an update.
To provide an overview of recently published work on autologous hematopoietic stem-cell transplantation (HSCT) in patients with systemic sclerosis (SSc).
Medical and Biotech [MESH] Definitions
Hematopoietic Stem Cell Transplantation
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Hematopoietic Stem Cell Mobilization
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Bone Marrow Transplantation
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Cord Blood Stem Cell Transplantation
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
Peripheral Blood Stem Cell Transplantation
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
